Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Army
Cerilliant
US Department of Justice
UBS
Chinese Patent Office
Citi
Deloitte
Mallinckrodt
Covington

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,427,633

« Back to Dashboard

Which drugs does patent 7,427,633 protect, and when does it expire?

Patent 7,427,633 protects CAYSTON and is included in one NDA.

This patent has thirty-nine patent family members in eighteen countries.
Summary for Patent: 7,427,633
Title:Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Abstract:A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Seattle, WA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:11/732,234
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery;

Drugs Protected by US Patent 7,427,633

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead CAYSTON aztreonam FOR SOLUTION;INHALATION 050814-001 Feb 22, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,427,633

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,399,496 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
6,660,249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
9,533,000 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
7,138,419 Process for manufacturing bulk solutions and a lyophilized pure .alpha.-aztreonam lysinate ➤ Subscribe
8,841,286 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
7,214,364 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
7,208,141 Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
9,345,663 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,427,633

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1641436 ➤ Subscribe
Portugal 2301524 ➤ Subscribe
Portugal 1641436 ➤ Subscribe
Portugal 1353647 ➤ Subscribe
Norway 20101377 ➤ Subscribe
Norway 2011001 ➤ Subscribe
Norway 329643 ➤ Subscribe
Norway 20032946 ➤ Subscribe
Luxembourg 91851 ➤ Subscribe
Japan 2007527398 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Fish and Richardson
Chubb
UBS
Harvard Business School
Dow
QuintilesIMS
Boehringer Ingelheim
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot